No peptide has been tested on human tendon pain in a controlled trial, so nobody can say whether BPC-157 or TB-500 heals tendonitis. The tendon evidence is rat Achilles surgery, and in the only study that ran both compounds head to head (32 rats, Biçer 2026), TB-500 alone produced the strongest repaired tendon on mechanical testing while the BPC-157 plus TB-500 combination did not beat TB-500 on its own. The strongest human evidence anywhere on this page is a 1998 heel-drop study: 15 people with chronic Achilles pain did 12 weeks of slow heel drops and all 15 returned to full running, while all 15 conventionally treated comparators ended up in surgery.
Peptides commonly discussed for tendonitis
Safety: A tendon that gave way with a pop, a gap you can feel, or an inability to push off or stand on tiptoe on one leg may be a rupture and needs urgent orthopaedic assessment rather than a protocol. Get a diagnosis before loading or injecting anything: a hot swollen joint with fever, night pain that wakes you, unexplained weight loss, numbness, or new tendon pain after a fall over age 50 all belong with a clinician first. BPC-157 and TB-500 are not FDA-approved for any human use, BPC-157 has been in Category 2 of the FDA's interim 503A bulk substances list since 29 September 2023, and the July 2026 advisory committee vote is advice to the agency that still requires HHS sign-off and formal rulemaking before it changes anything legally. Both are sold only as research chemicals labelled not for human consumption. No clinical safety data exist for BPC-157 in humans, which means no toxicology, no long-term follow-up, no pregnancy or paediatric data and no established contraindications or interactions; both compounds act on tissue growth and cell migration, an unresolved question for anyone with a current or previous cancer. No published protocol supports self-injection into or around a tendon or joint, and both compounds are prohibited in tested sport at all times. Never stop a prescribed anti-inflammatory because of anything on this page; raise it with the prescriber. This page is education, not medical advice.
Where to buy
Where to get peptides for tendonitis
Save 10% at checkout with code tcwisiiu
Some links are affiliate links — we may earn a fee at no extra cost to you. Most peptides aren't FDA-approved — consult a qualified clinician and check your local laws before purchasing.
No controlled trial has ever given BPC-157 to a person with a painful tendon, so nobody can say whether it helps tendonitis 1. What exists is rat surgery, and the one rat study that ran BPC-157 against TB-500 ranked them in the opposite order from the protocols people copy online 3.
Why a sore tendon takes months to do what a pulled muscle does in weeks
Tendon is rope: densely packed collagen fibres running in one direction, relatively few living cells scattered between them, and a thin blood supply compared with the muscle it attaches to. Muscle is the opposite, cell-rich and vessel-rich and quick to rebuild, and that difference sets the clock. Repair cells reach a tendon slowly and in small numbers, and the collagen they lay down takes months of loading before it is pulled into line and can carry force again.
Every peptide pitch for tendons aims at that bottleneck. BPC-157 is credited in animal models with growing capillaries into damaged tissue and raising expression of growth pathways, and TB-500 with getting repair cells to migrate through whatever blood supply exists 1. The mechanism story is coherent, and the human evidence for it does not exist.
What goes wrong in a painful tendon
The word tendonitis names a problem most sore tendons do not have
The suffix in tendinitis means inflammation, and in chronic cases the inflammation is largely absent. Khan and colleagues made that argument in the British Medical Journal in 2002 under the title "Time to abandon the 'tendinitis' myth", which is why sports medicine now writes tendinopathy or tendinosis for long-standing cases 2. Naming matters here because the name drives the treatment reflex: ice, ibuprofen, a cortisone shot, rest until it stops hurting.
That editorial is also the most commonly misquoted source in this whole subject. It runs two pages, it is an opinion piece about terminology, and it reports no resolution rate of any kind. If you have seen a claim that some percentage of tendonitis fails first-line care attributed to Khan 2002, that number is not in the paper 2. Nobody has pinned a reliable figure on how often tendinopathy stalls, which is worth knowing before you accept a marketing page's estimate of how many people need something stronger.
What the evidence is, option by option
| Option | Best evidence for tendons | Species and size | What it showed | Evidence tier |
|---|---|---|---|---|
| Heavy slow eccentric loading | Alfredson 1998, 12 weeks of heel drops 7 | Humans, 15 treated plus 15 comparators | All 15 returned to pre-injury running; all 15 treated conventionally ended up in surgery | Human, non-randomised, small, and the standard of care since |
| Progressive loading with a physiotherapist | Extension of the same loading principle to elbow, knee and shoulder tendons | Humans | Directs how the new collagen aligns; the transfer beyond the Achilles is clinical convention | Human for the Achilles, convention elsewhere |
| Collagen peptides by mouth | Randomised human trials exist for joint pain rather than tendon pain (see our joint pain page) | Humans, hundreds across trials | Trials in people with knee pain reported modest changes in self-reported comfort; no trial measured tendon structure. Collagen peptides are a food supplement and are not offered here as a treatment for any condition | Human, but measured in a different tissue |
| BPC-157 | Staresinic 2003 rat Achilles transection 4, Krivic 2006 tendon-to-bone 5, Biçer 2026 head-to-head 3 | Rats; 8 per arm in the head-to-head | Higher load to failure (more force before the tendon tore) and better collagen organisation versus saline; numerically better but not statistically significant on total scores in the 2026 head-to-head | Animal only. One clinical study in the entire musculoskeletal literature, a retrospective knee-pain review 1 |
| TB-500 | Biçer 2026 3 | Rats, 8 per arm | The only arm to reach significance on maximum load to failure (p < 0.05), with lower Bonar (p = 0.016) and Movin (p = 0.017) scores, the pathologists' degeneration grading systems | Animal for tendon. Human trials tested the full-length parent protein in eyes 6 and on skin ulcers 11 |
| GHK-Cu | No tendon study identified in the reviewed literature | None | Its human record is topical use on skin | None for tendon |
| NSAIDs (ibuprofen, naproxen) | Su and O'Connor 2013 review 8 | Animal and cell models; few human studies | Reliable pain relief; impaired tendon healing in multiple animal models | Animal for healing, human for pain |
| Corticosteroid injection | Krivic 2006, methylprednisolone arm 5 | Rats | Consistently made tendon-to-bone healing worse | Animal, consistent with long-standing clinical caution |
Read the table as a ranking and it says one uncomfortable thing. The only option on it with a human result is the one that costs nothing, and the two compounds people pay for sit a whole species below it. With a sore Achilles and three hundred dollars, the heel drops are not the consolation prize.
The one head-to-head study put TB-500 in front of BPC-157, in rats
Biçer and colleagues cut and repaired the Achilles tendon in 32 male rats, then split them into four groups of eight: control, BPC-157 at 10 mcg per kg per day, TB-500 at 60 mcg per kg per day, and both together. Every dose went into the abdominal cavity daily for four weeks, after which the tendons were pulled to failure on a testing rig or sectioned for a pathologist 3.
TB-500 alone was the only group whose maximum load to failure, meaning how much force the repaired tendon took before it tore on that rig, beat the controls by more than chance could explain, which is what statistically significant means (p < 0.05). It also had significantly lower total Bonar (p = 0.016) and total Movin (p = 0.017) scores, the two grading systems pathologists use to rate how degenerate a tendon looks under a microscope. The combination group reached significance on total Movin score as well (p = 0.040), but the authors report that combining the two conferred no additional benefit over either agent alone. BPC-157 alone improved the same measures a little, and not by enough to rule out luck with eight animals per group 3.
Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.
BPC-157 versus TB-500 for a tendon, on the record rather than the marketing
Hold the finding at its actual weight. Eight rats per arm, four weeks, one laboratory, and the authors call it exploratory themselves; they suggest the missing additive effect may mean the two compounds converge on the same downstream pathways, and say that hypothesis needs confirming 3. It does not show TB-500 works better in people, because no study has given either compound to a person with a tendon injury. What it does undercut is the ordering that circulating stacks assume, where BPC-157 leads and TB-500 is the optional add-on.
That assumption is what the popular tendon blend is built on. Named combinations like it circulate widely, and listing one below is not an endorsement: the only study to test BPC-157 and TB-500 together found the combination added nothing over either compound alone 3.
The rat Achilles study everyone quotes contains no percentage
Staresinic and colleagues cut the right Achilles tendon of rats 5 mm above its attachment to the heel bone, leaving a visible gap between the cut ends. BPC-157 went into the abdominal cavity once daily at 10 mcg, 10 ng or 10 pg per kg, starting 30 minutes after surgery, and the tendons were assessed on days 1, 4, 7, 10 and 14 against saline controls. Treated rats had higher load to failure, higher load per unit area, a higher elastic modulus (a measure of stiffness), better collagen and fibroblast formation, and a smaller tendon defect 4.
The paper reports measured values rather than a headline percentage improvement, so any "BPC-157 improved tendon healing by X percent" figure attributed to it was invented downstream. The same study also ran cultured tendon cells, where BPC-157 on its own had no effect on cell growth. What it did was reverse the growth-blocking effect of 4-hydroxynonenal, a toxic breakdown product of damaged fats 4.
The corticosteroid finding is the one worth carrying to a doctor
Krivic and colleagues used a different injury: the rat Achilles was cut away from the heel bone entirely, a tendon-to-bone detachment rather than a tear in the middle of the tendon. Groups received BPC-157 (10 mcg, 10 ng or 10 pg per kg), the steroid methylprednisolone at 1 mg per kg, saline, or combinations, into the abdominal cavity daily, with outcomes read at days 1 through 21. BPC-157 improved function, load to failure, stiffness and collagen organisation. The steroid consistently made healing worse, and BPC-157 substantially reduced that steroid damage 5.
The half of that finding you can act on today has nothing to do with peptides. If a cortisone injection is on the table for a tendon, the animal literature says the steroid buys pain relief against the tendon's own repair, which is a fair question to put to the clinician offering it. A joint capsule is not a tendon and the calculation changes: our joint pain page works through the injection evidence for arthritic and diffuse joint pain, where the human trial record is larger and the questions are different.
TB-500's human trials were eye drops
TB-500 is sold as a synthetic fragment of thymosin beta-4, a 43-amino-acid protein that binds actin, the protein cells use to crawl. The parent protein does have randomised human data. Sosne and colleagues ran a phase 2 trial of thymosin beta-4 eye drops at 0.1 percent, six times daily for 28 days, in 9 patients with severe dry eye, and reported a 59.1 percent reduction in corneal staining (the dye test that shows damage to the surface of the eye) versus vehicle, p = 0.0108, measured at day 56, which was 28 days after dosing ended, across 12 treated eyes and 6 vehicle eyes 6. A separate double-blind, placebo-controlled phase 2 study by Guarnera and colleagues applied it topically to venous leg ulcers in 73 patients randomised across eight European sites, five in Italy and three in Poland 11.
Neither trial involved a tendon, neither used the shortened fragment sold as TB-500, and neither injected it. That is the entire randomised human record for this molecule, and stacking it against tennis elbow requires assuming the fragment behaves like the parent protein, that an eye and a tendon are comparable tissues, and that injection matches topical delivery. Nobody has checked any of those three.
The intervention with human data is a free 1998 heel-drop programme
Alfredson and colleagues took 15 recreational athletes with a mean age of 44, all with chronic Achilles tendinosis and long-standing symptoms that had already failed conventional care, and gave them 12 weeks of heavy-load eccentric calf training 7. The programme was 3 sets of 15 heel drops, twice a day, seven days a week for 12 weeks, done once with a straight knee and once with a bent knee, lowering slowly off a step and letting the other leg do the lift back up, and continued into discomfort rather than stopped at it. After 12 weeks all 15 were back at their pre-injury running level, pain during activity had dropped significantly, and calf strength on the injured side no longer differed from the healthy side 7.
In no case was the conventional treatment successful, and all patients were ultimately treated surgically.Alfredson and colleagues on their 15 comparison patients, American Journal of Sports Medicine, 1998 [[7]]
The study had 15 people, no randomisation, and a comparison group treated separately rather than concurrently, so it would not pass today's design standards. It is still the strongest human evidence anywhere on this page, it has been the basis of standard care for mid-portion Achilles tendinopathy ever since, and the mechanism matches the pathology: load is the signal that pulls new collagen into line. A physiotherapist can adapt the same principle to an elbow, knee or shoulder tendon and load it correctly, which is the referral worth asking for before any vial. For an acute structural injury rather than a tendon that has ached for months, our injury recovery page covers a different timeline and a different set of red flags.
Where anti-inflammatories fit, and exactly where the evidence stops
Su and O'Connor reviewed what NSAIDs do to healing in bone, tendon and the tendon-to-bone junction. These drugs block cyclooxygenase and cut production of prostaglandins, signalling molecules that drive both inflammation and parts of the repair response, and across animal and cell models that showed up as impaired tendon healing. Human studies on healing (as opposed to pain) are few, and the authors note that different drugs, doses and outcome measures make the studies hard to compare 8.
No study in any species has measured what happens when an NSAID and BPC-157 are given together, so every percentage quoted for that interaction was invented by somebody. What survives is a reasonable question for your prescriber about whether a daily painkiller is still earning its place while a tendon is rebuilding. Our page on inflammation covers the wider signalling picture and where the same evidence gaps sit.
What the research protocols used, and what circulates instead
| Source | Compound | Dose used | Route | Duration | Species |
|---|---|---|---|---|---|
| Staresinic 2003 4 | BPC-157 | 10 mcg, 10 ng or 10 pg per kg, once daily | Intraperitoneal (into the abdominal cavity) | Assessed to day 14 | Rat |
| Krivic 2006 5 | BPC-157 | 10 mcg, 10 ng or 10 pg per kg, once daily | Intraperitoneal | Assessed to day 21 | Rat |
| Biçer 2026 3 | BPC-157 | 10 mcg per kg per day | Intraperitoneal | 4 weeks | Rat |
| Biçer 2026 3 | TB-500 | 60 mcg per kg per day | Intraperitoneal | 4 weeks | Rat |
| Sosne 2015 6 | Thymosin beta-4, full length | 0.1 percent drops, 6 times daily | Eye drop | 28 days | Human |
| Protocols circulating online | BPC-157 | 250 to 500 mcg per day | Subcutaneous | 6 to 12 weeks | None. No study produced these figures, no human dose-finding trial exists, and no dose is known to be safe or effective. Listed to show what circulates |
The online numbers are not a conversion of the animal numbers. A 10 mcg per kg daily dose into a rat's abdomen is not the arithmetic source of 250 to 500 mcg subcutaneously in a person, no dose-finding study has been run in humans, and current reviews describe no approved formulation and no validated dosing regimen 1. Our BPC-157 dosage guide traces how those figures entered circulation, the half-life page covers why a compound with a half-life under 30 minutes, metabolised in the liver and cleared by the kidneys, gets dosed once a day anyway 1, and our peptide cycling guide covers where the 8 to 12 week on-off schedules came from, which is not from any study.
Cost, storage, and the sourcing problem
Both compounds are sold as research chemicals rather than medicines, which means no pharmaceutical manufacturing standard stands behind the label. That phrase is literal. Vials are sold for laboratory use and labelled not for human consumption, so buying one to inject means stepping outside every approved supply channel, with the legal and product-quality risk that carries. We describe this market because readers encounter it, not to help anyone shop in it. A batch-specific certificate of analysis is the minimum any buyer asks for, because nothing else establishes what is in the vial, and the 2025 systematic review names unregulated manufacturing and contamination as the concrete safety concern, ahead of any pharmacology 1.
- Storage: supplied as a lyophilised (freeze-dried) powder that is kept refrigerated and protected from light, and refrigerated again once mixed with bacteriostatic water. We cover handling and sterile technique elsewhere on the site, for readers who have already made that decision with a clinician.
- Cost: listed prices vary widely between research suppliers, and vial pricing is the smallest part of the decision given that no dose known to be safe or effective in humans exists. The loading programme with the human data behind it costs nothing.
- Time to any signal: the rat studies measured at 14 days, 21 days and 4 weeks 4 5 3. Human tendon remodelling runs for months, and tendinopathy also improves on its own in many people, which makes personal before-and-after timelines almost impossible to attribute.
- Side effects: there is no human safety record for either compound. No toxicology in people, no long-term follow-up, no pregnancy or paediatric data, and no established contraindications or drug interactions, because the studies that would define them have not been run. Preclinical work in animals reported no adverse effects across several organ systems, and the same review found no clinical safety data at all 1. Anecdotal accounts mention injection-site reactions and headache, but anecdote is not safety surveillance. Both compounds act on tissue growth and cell migration, an unresolved theoretical concern for anyone with a current or previous cancer.
No clinical safety data were found.Vasireddi and colleagues, on their systematic review of the entire BPC-157 musculoskeletal literature, HSS Journal, 2025 [[1]]
Absence of reported harm in rats is not a human safety record. That gap sits awkwardly beside the 8 to 12 week schedules circulating online, and it is the strongest argument for keeping a clinician in the loop rather than a forum. Disclosure: some links elsewhere on this site, including any DNA-kit offer shown alongside this page, are affiliate links, and PeptidesDNA may earn a commission if you buy through them. We do not sell peptides, no vendor pays for placement, and nothing above was written to sell anything.
Why two runners with the same mileage get different Achilles outcomes
Some of the difference in who develops tendon trouble is inherited. Mokone and colleagues genotyped 111 people with Achilles tendon pathology and 129 controls at COL5A1, the gene for one chain of type V collagen, a minor collagen that regulates how thick and how orderly the main type I fibres end up. One version of the gene (alleles are the alternative versions you can inherit at a given spot in the DNA) accounted for 29.8 percent of the gene copies counted in controls but only 18.0 percent in patients, so carrying it looked roughly protective, on the order of half the injury risk in this sample, and the protection looked stronger still in the 72 people with chronic Achilles tendinopathy 9. This was a candidate-gene study in Caucasian participants at a single South African centre rather than a genome-wide or multi-ancestry result, later studies of the same region have not all agreed, and the variant most consumer arrays report there is rs12722.
That variant predicts susceptibility to tendon injury, not response to any compound. No study in any species has tested whether a genotype predicts response to BPC-157 or TB-500, and the rat work does not genotype animals at human variants. Related markers you may see attached to tendon pages, in the collagen-breakdown enzyme MMP1 or the blood-vessel growth factor VEGFA, sit at the same level: pathway plausibility with no response data behind them.
The one thing a tendon-risk genotype could change is how you plan, not what you buy. If tendon problems have recurred and run in your family, the useful adjustments are a slower load-progression rule, a longer rehab horizon before returning to full speed, and earlier imaging when something new starts, because the loading has human evidence and the compounds do not. Our DNA decision framework sets out the same test applied across every peptide: what a marker is associated with, whether anyone has tested it against a response, and what changes if the answer is no.
Signs that mean stop researching and get it examined
One more constraint applies if you compete. BPC-157 and TB-500 are both prohibited in tested sport at all times, in and out of competition: BPC-157 under S0, the non-approved substances category, and thymosin beta-4 and its derivatives, TB-500 among them, under S2.3, growth factors and growth factor modulators 12. Sanctions in that system can be non-analytical, meaning possession, an order confirmation or an admission can be enough without a positive test.
Related pages if you want to go further or step back: joint pain if the ache is diffuse or arthritic rather than one tendon, where the human trial record is larger and mostly about injections into the joint; injury recovery for an acute structural injury, where the timeline and the warning signs are different; best peptides for healing for how these two rank against everything else marketed for repair; best peptides for muscle recovery if the sore tendon is really a training-load problem across the whole body; and BPC-157 and TB-500 for the full compound records, including the human studies that exist in other tissues.
Your DNA cannot tell you whether BPC-157 or TB-500 will work on a tendon, because nobody has run that study. What it can show is where published research links your variants to collagen structure, injury susceptibility and recovery speed, and which of the 39 peptides have any genetic signal behind them at all. Upload the raw DNA data you already have.
See what your DNA does and doesn't say- The head-to-head reverses the ranking the protocols assume
Circulating tendon protocols lead with BPC-157 and treat TB-500 as the optional add-on. In the only study that ran both, in 32 rats with surgically repaired Achilles tendons, TB-500 alone was the single arm to reach statistical significance on how much force the repaired tendon could take, and the authors report that combining the two added nothing over either one alone.
- A chronically sore tendon is usually not inflamed
Biopsies of long-standing tendon pain show disorganised collagen and altered tendon cells rather than inflammatory cells, which is why the '-itis' name pushes people toward ice, ibuprofen and cortisone, three things aimed at a target that has already left.
- Twelve weeks of heel drops has the best evidence on this page
Twelve weeks of slow heavy heel drops returned all 15 chronic Achilles patients in the founding 1998 study to full running while all 15 conventionally treated patients ended up in surgery. No peptide named here has been given to a single human tendon in a controlled trial.
Frequently asked questions
Can BPC-157 help with tendonitis?
Nobody can answer that from evidence, because BPC-157 has never been given to a person with a painful tendon in a controlled trial. The tendon research is rats whose Achilles tendon was cut surgically and who received the compound into the abdominal cavity, where it improved load to failure and collagen organisation against saline controls. A 2025 systematic review of BPC-157 across all musculoskeletal use found 36 studies, 35 of them preclinical, and the one clinical entry is a retrospective note on 12 people who had a knee injection for unspecified chronic knee pain.
Will BPC-157 heal a tendon, or only speed up what loading was going to do anyway?
That question has never been tested, in any species, because no study has compared BPC-157 against a proper loading programme. Tendinopathy improves on its own in a large share of people, and the loading programme that has human data behind it takes about 12 weeks, which is the same window most peptide protocols run. Any personal before-and-after over that period cannot separate the compound from the rehab or from time.
Is the BPC-157 and TB-500 stack better than one alone?
In the only study that has tested it, no. Biçer and colleagues ran 32 rats through four arms after Achilles repair and reported that combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone, while TB-500 by itself was the arm with the significant gain in maximum load to failure. The combination arm did beat controls on one histology score, but the authors call the work exploratory and suggest the two compounds may act on the same downstream pathways, which would explain why adding them together achieves nothing extra. No human comparison exists.
Are BPC-157 and TB-500 banned in sport, and can you be sanctioned without a positive test?
Both are prohibited at all times for athletes under the WADA Prohibited List, in competition and out of it: BPC-157 under S0 as a non-approved substance, and thymosin beta-4 and its derivatives under S2.3, growth factors. There is no off-season window. Sanctions in that system can also be non-analytical, meaning an admission, a delivery record or possession can support a case without any positive test result.
Sources12
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025;21(4):485-495.
- Khan KM, Cook JL, Kannus P, Maffulli N, Bonar SF. Time to abandon the "tendinitis" myth. BMJ, 2002;324(7338):626-627.
- Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026;37(3):822-837.
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 2003;21(6):976-983.
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research, 2006;24(5):982-989.
- Sosne G, Dunn SP, Kim C. Thymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea, 2015;34(5):491-496.
- Alfredson H, Pietilä T, Jonsson P, Lorentzon R. Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis. American Journal of Sports Medicine, 1998;26(3):360-366.
- Su B, O'Connor JP. NSAID therapy effects on healing of bone, tendon, and the enthesis. Journal of Applied Physiology, 2013;115(6):892-899.
- Mokone GG, Schwellnus MP, Noakes TD, Collins M. The COL5A1 gene and Achilles tendon pathology. Scandinavian Journal of Medicine and Science in Sports, 2006;16(1):19-26.
- US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (bulk drug substances nominated for use in compounding under section 503A).
- Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences, 2010;1194:207-212.
- World Anti-Doping Agency. The Prohibited List (S0 non-approved substances; S2.3 growth factors and growth factor modulators, including thymosin beta-4 and its derivatives).
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
This page is educational and is not medical advice. Peptides are not intended to diagnose, treat, cure, or prevent any disease, and most are not FDA-approved. Talk to a qualified healthcare provider before starting anything. Availability and legal status of peptides vary by jurisdiction.
← All condition guides